Manulife Financial (MFC): Q1 2026 Earnings Preview and What Investors Should Watch
Key Takeaways
- Analysts expect Q1 2026 core EPS of C$1.09, up 10% from C$0.99 in Q1 2025.
- 12 analysts contribute to the consensus, with estimates ranging from C$0.99 to C$1.14.
- Manulife's stock has gained over 10% year-to-date, outperforming broader markets amid strong insurance sales momentum.
- Focus on Asia segment growth, core ROE (return on equity), and LICAT ratio (life insurance capital adequacy test).
- Historical beats in recent quarters, including Q4 2025 EPS of US$0.80 vs. US$0.76 expected.
- Earnings due after market close on May 13, 2026, with conference call on May 14.
Understanding the Earnings Context
Manulife Financial (MFC), one of the leading global life insurers, will report its Q1 results for the period ended March 31, 2026, on May 13. From what I see, this release will provide insight into whether the company can sustain the momentum from 2025's record core earnings of C$7.5 billion, which rose 3% on a constant exchange rate basis. With shares up over 10% year-to-date and trading near 52-week highs around US$40, investors are looking for confirmation of strong sales in Asia, growth in wealth management fees, and resilient margins despite shifting interest rates. In a competitive insurance market, MFC's emphasis on high-return areas like Asia and its global wealth and asset management (WAM) business sets it apart. Key indicators such as APE (annualized premium equivalent) sales and new business CSM (contractual service margin) will reveal demand trends, while the LICAT ratio will highlight capital strength supporting dividends and buybacks.
What to Expect from Q1 Earnings
The consensus points to Q1 2026 core EPS of C$1.09, marking 10% growth from C$0.99 in Q1 2025 (estimated at C$0.98, with a slight beat on the actual). This forecast draws from 12 analysts, whose estimates span C$0.99 on the low end to C$1.14 on the high. Revenue figures aren't widely available for the quarter, though full-year 2026 projections sit around C$50 billion. I think core earnings growth will hinge on insurance new business—APE sales jumped 37% last year—and fee-related flows in WAM.
MFC has shown a mixed but generally positive history of beating estimates: Q4 2025 EPS came in at US$0.80 versus US$0.76 expected, Q3 2025 beat by US$0.10, though Q1 2025 was a slight miss. Post-earnings stock moves have been muted on average, with attention turning to guidance on core ROE above 15% and LICAT over 130%.
Market Sentiment Ahead of Earnings
Heading into this report, sentiment around MFC feels cautiously optimistic—shares are up 10% year-to-date, and analyst ratings lean toward buy. Options pricing suggests a modest ~4% move post-earnings, indicating tempered expectations. Potential risks include foreign exchange headwinds from a strong CAD, elevated credit losses, or weaker demand in Asia. Past beats have tended to lift the stock, but misses like Q2 2025 triggered pullbacks. The current elevated implied volatility captures the usual pre-earnings caution.
AI Screener: My Go-To Tool for Comparison
I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. This AI-powered tool scans stocks and ETFs based on technical patterns, fundamentals, trends, volatility, and AI signals, letting you filter by industry, market cap, indicators, and more. It surfaces trade ideas and opportunities faster than manual reviews, which has been helpful in my analysis. If you're screening for insurance names or similar setups, it's worth exploring.
Looking Ahead: Key Metrics and Outlook
After Q1 results, one thing that stands out is the updated guidance on full-year core EPS growth and mid-teens ROE targets. MFC's 10.2% dividend increase in 2025 to C$0.485 per share reflects confidence in capital returns, alongside ongoing NCIB buybacks.
Asia continues to be pivotal, with prior surges in APE sales pointing to lasting demand. I'll be watching new business CSM and NBV (new business value) for signs of profitability in these growth markets. In WAM, fee revenue and AUM growth amid equity market rallies will matter a great deal.
Capital metrics remain a strength—LICAT at 137% in recent quarters and solid leverage—but keep an eye on ECL (expected credit losses) and investment spreads in this rate environment. Broader industry factors like reinsurance and regulations could affect margins. Future catalysts include Q2 results in August and updates on Asia expansion; I'm watching this closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Momentum Indicator for MFC turns negative, indicating new downward trend
MFC saw its Momentum Indicator move below the 0 level on August 17, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned negative. In of the 78 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for MFC moved out of overbought territory on August 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for MFC turned negative on August 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MFC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MFC advanced for three days, in of 341 cases, the price rose further within the following month. The odds of a continued upward trend are .
MFC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 338 cases where MFC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.090) is normal, around the industry mean (1.401). P/E Ratio (15.911) is within average values for comparable stocks, (20.657). Projected Growth (PEG Ratio) (0.870) is also within normal values, averaging (1.271). Dividend Yield (0.032) settles around the average of (0.046) among similar stocks. P/S Ratio (1.721) is also within normal values, averaging (1.312).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MFC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of life and health insurance and reinsurance services
Industry LifeHealthInsurance
Advertisement